Sun Mar 1 10:55:44 SGT 2015  
SINGAPORE
STD
    Genital Warts
SINGAPORE STD ™
Within 3 days after unprotected sex, stop HIV infection with Post-Exposure Prophylaxis treatment
28 days after unprotected sex, accurately detect HIV infection with the 20 minute rapid test
Full & comprehensive sexually transmitted disease testing

Genital Warts | SINGAPORE STD ™

Summary

Genital Warts | SINGAPORE STD ™ @singaporestd_com: Genital warts, Singapore. Private & confidential service.

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
SHIM CLINIC
SINGAPORE STD ™
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Genital Warts | SINGAPORE STD ™
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

Description

Table of Contents

Genital warts: penile warts / vaginal warts / anal warts / anogenital warts / venereal warts / condyloma / condylomata acuminata / "cauliflower" sex disease.

References

Warts - on male sex organ Genital warts appear within 3 months after sexual contact with an infected person.

Genital warts:

  • are usually soft, pink cauliflower-like growths or flesh-coloured bumps on the sex organs
  • may also be hard and smooth
  • occur alone or in groups
  • tend to recur after treatment
  • increase the risk of cervical cancer in women.


Warts - on female sex organ An infected woman may infect her newborn during childbirth.

A person with genital warts can infect others through sexual contact.



Genital warts treatment / HPV treatment

HPV / human papillomavirus.

  • 120 known human papillomavirus (HPV)
  • 51 HPV types, and 3 subtypes are genital HPV as they infect the genital mucosa.
  • 31 genital HPV types are low risk
  • 6 genital HPV types are intermediate risk
  • 17 genital HPV types are high risk
They cause Genital HPV types, cancer risk, vaccine and test coverage
Type
Species
Risk
Cervarix
Gardasil
Gardasil-9
DigeneHR
DigenePS
CobasHPV
Digene
HybriBio
PapilloCheck
InnoLiPA
LinearArray
61 3 L ----------+-
72 3 L ----------+-
81 3 L -------+--+-
83 3 L ----------+-
84 3 L ----------+-
62 3 L ----------+-
CP6108 3 L ----------+-
71 15 L ---------++-
26 5 H ---------++-
51 5 H ---+-++++++-
69 5 H ---------++-
82 5 H --------+++-
IS39 5 H ----------+-
18 7 H +++++++++++-
39 7 H ---+-++++++-
45 7 H --+++++++++-
59 7 H ---+-++++++-
68 7 H ---+-++++++-
70 7 H --------+++-
53 6 H -------++++-
56 6 H ---+-++++++-
66 6 H -----+-++++-
54 13 L ---------++-
42 1 L ------+++-+-
40 8 L --------+++-
43 8 L ------++++--
6 10 L -++---+++++-
11 10 L -++---+++++-
44 10 L ------++++--
74 10 L ---------+--
16 9 H +++++++++++-
31 9 H --++-++++++-
33 9 H --++-++++++-
35 9 H ---+-++++++-
52 9 H --++-++++++-
58 9 H --++-++++++-
67 9 H ----------+-
73 11 H --------+++-

Legend: 71 (CP 8061), 73/MM9, 81 (CP 8304), 82 (MM4), 82 (IS 39), 83 (MM7), 84 (MM8), 89 (CP 6108)

References

Cervical cancer HPV vaccine (previously known as cervical cancer vaccine) types:
  • Gardasil® [HPV (Human Papillomavirus) Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]
  • Cervarix® [HPV (Human Papillomavirus) Bivalent (Types 16 and 18) Vaccine, Recombinant]
  • V503 [HPV (Human Papillomavirus) Nonavalent (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) Vaccine, Recombinant]
References Gardasil® [HPV (Human Papillomavirus) Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] References Cervarix® [HPV (Human Papillomavirus) Bivalent (Types 16 and 18) Vaccine, Recombinant] References V503 [HPV (Human Papillomavirus) Nonavalent (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) Vaccine, Recombinant] - to be released in 2013 STD vaccine / hepatitis vaccine shot/jab/injection to prevent some STDs

Vaccine Against Disease Age D
o
s
e
s
Dose schedule Price
per
dose
(SG$)
Havrix™ 1440 Adult Hepatitis A virus Hepatitis A ≥19y 2 m 0 & 6-12 $90/=
Twinrix® Hepatitis A virus
Hepatitis B virus
Hepatitis A
Hepatitis B
1-15y 2 m 0, 6-12 $135/=
≥16y 3 m 0, 1, 6
4 d 0, 7, 21 & m 12
Inactivated / Fractional / Protein / Subunit / Recombinant
Engerix™-B 20 μg Hepatitis B virus Hepatitis B 11-15y 2 m 0, & 6 $50/=
≥20y 3 m 0, 1, & 6
4 m 0, 1, 2, & 12 or
d 0, 7, 21 & m 12
Gardasil® HPV
types 6, 11, 16, & 18
Genital warts
Cervical cancer
9-26y 3 m 0, 2, & 6 or
m 0, 1, & 4
$195/=
Cervarix® HPV
types 16, & 18
(31, 33, & 45)
10-25y 3 m 0, 1, & 6
m 0, 1, & 5
m 0, 2½, 12
$195/=
V503 HPV
types 6, 11, 16, 18,
31, 33, 45,
52, & 58
3 m 0, 2, & 6 or
m 0, 1, & 4
$???/=

HPV test for men/women.

  • Digene® High-Risk HPV DNA Test
  • Digene® HPV DNA Test
  • Digene® HPV Genotyping PS Test
  • Hybribio®
    • HPV GenoArray Test Kit
    • Detects 15 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, and 68. And 6 low-risk HPV types: 6, 11, 42, 43, 44, CP8304
    • Able to differentiate which types are positive.
    • May be available in Singapore soon.
  • Cobas® HPV Test
    • Cobas® HPV Test
    • Detects 14 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68
    • The test specifically identifies (types) HPV 16 and HPV 18, while concurrently detecting the rest of the high risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)
    • Cost is SG$200/=
  • LINEAR ARRAY® HPV Genotyping Test
    • LINEAR ARRAY® HPV Genotyping Test
    • Identifies 37 high-risk HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73 (MM9), 82 (MM4) low-risk HPV genotypes 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 83 (MM7), 84 (MM8), IS39, and CP6108
  • INNO-LiPA HPV Genotyping Extra
    • INNO-LiPA HPV Genotyping Extra
    • Identifies 15 high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82) 3 probable high-risk HPV genotypes (26, 53, 66) 7 low-risk HPV genotypes (6, 11, 40, 43, 44, 54, 70) and some additional types (69, 71, 74).
  • PapilloCheck®
    • PapilloCheck®
    • Identifies 24 hiv-risk HPV types 16 18 31 33 35 39 45 51 52 53 56 58 59 66 68 70 73 82 and low-risk HPV types 6 11 40 42 43 44

Sexual risk (of HIV/STD/pregnancy), and what you can do before and after exposure.

Timeline HIV STD Pregnancy
Before exposure
Abstain from sex, Be faithful, or Condom use
Circumcision (males only)
Contraception (females only)
HIV PrEP (pre-exposure prophylaxis) STD vaccine:
- Hepatitis vaccine
- HPV vaccine
STD / HIV exposure
Unsafe sex / unprotected sex:
No condom / Condom broke / Condom slip
0-72 hours HIV prevention
HIV PEP (post-exposure prophylaxis) treatment
- Stop HIV infection after exposure.
STD testing.
If STD symptoms appear, then do STD treatment.
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.
Emergency contraception (females only)
2 weeks HIV DNA PCR test
1 month 20 minute HIV rapid test - SD Bioline HIV Ag/Ab Combo:
- Fingerprick blood sampling.
3 months 20 minute HIV rapid test - OraQuick®:
- Oral saliva or
- Fingerprick blood sampling.
Full & comprehensive STD testing
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.

References


Latest News

Human Papillomavirus Vaccination: A Preventative Health Interest for Plastic Surgeons
Sat, 28 Feb 2015 09:22:35 +0100 | Plastic and Reconstructive Surgery
No abstract available (Source: Plastic and Reconstructive Surgery)

The pathology of HPV-related head and neck Cancer: Implications for the diagnostic pathologist
Sat, 28 Feb 2015 00:00:00 +0100 | Seminars in Diagnostic Pathology
A subset of head and neck squamous cell carcinoma are caused by the human papillomavirus (HPV). This HPV-related form of head and neck squamous cell carcinoma (HPV-HNSCC) has captured the attention of the oncology community for its rising incidence, its link to non-traditional risk factors, and its divergent clinical behavior. To diagnose this special form of head and neck squamous cell carcinoma is to provide important prognostic information and, in some instances, redirect clinical therapy. The diagnosis of HPV-HNSCC is aided by a strong appreciation for its characteristic microscopic findings and by an awareness of aberrant features that set apart a growing list of HPV-HNSCC morphologic variants. (Source: Seminars in Diagnostic Pathology)

Predictors of Human Papillomavirus Awareness and Knowledge in 2013 Gaps and Opportunities for Targeted Communication Strategies
Sat, 28 Feb 2015 00:00:00 +0100 | American Journal of Preventive Medicine
Conclusions Although awareness and knowledge of HPV is increasing, there are opportunities to target communication with populations for whom knowledge gaps currently exist, in order to promote dialogue about the vaccine among patients and their providers. (Source: American Journal of Preventive Medicine)

A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
Fri, 27 Feb 2015 00:00:00 +0100 | Annals of Oncology
Conclusion

Development of anti-E6 pegylated lipoplexes for mucosal application in the context of cervical preneoplastic lesions
Fri, 27 Feb 2015 00:00:00 +0100 | International Journal of Pharmaceutics
In conclusion, pegylated anti-E6 lipoplexes have demonstrated their efficiency to cross the cellular membrane and to release siRNA into the cytoplasm confirmed by final p53 protein production. Graphical abstract (Source: International Journal of Pharmaceutics)

Merck’s 9-Valent HPV Vaccine, GARDASIL®9, Recommended by CDC’s Advisory Committee on Immunization Practices for Females Aged 9-26 and Males Aged 9-21
Thu, 26 Feb 2015 20:18:00 +0100 | Merck.com - Corporate News
Dateline City:

'Game changer' HIV drug cuts infection risk by 86%
Wed, 25 Feb 2015 13:00:00 +0100 | NHS News Feed
Conclusion

Oncogenic human papillomavirus is not helpful for cytology screening of the precursor lesions of anal cancers in Taiwanese men who are infected with human immunodeficiency virus
Wed, 25 Feb 2015 00:00:00 +0100 | International Journal of Clinical Oncology
Conclusions

Current Status of Clinical Trials in Head and Neck Cancer 2014
Wed, 25 Feb 2015 00:00:00 +0100 | Otolaryngology - Head and Neck Surgery
Conclusions

Prevalence of High risk Human Papillomavirus in cervical dysplasia and cancer samples from twin cities in Pakistan
Wed, 25 Feb 2015 00:00:00 +0100 | International Journal of Infectious Diseases
(Source: International Journal of Infectious Diseases)